Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Proposes CED Policy For Watchman With Some Unexpected Conditions

This article was originally published in The Gray Sheet

Executive Summary

The proposed national coverage decision for the left-atrial appendage closure stroke device would grant Medicare coverage with stipulations, including one provision that appears to contradict a key element of FDA labeling and a challenging registry requirement.

Advertisement

Related Content

Boston Sci's Watchman Gets Positive Medicare Coverage Policy
Boston Sci's Watchman Gets Positive Medicare Coverage Policy
Voices From TCT 2015: Ken Stein On The Future Of Watchman
Drug-Coated Balloons Net Medicare Inpatient Bonus Payments
Boston Sci’s Watchman Stroke Device Finally Lands FDA Approval, With Favorable Labeling

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT034374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel